Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study.
about
Lupus Nephritis: A Different Disease in European Patients?Update on the treatment of focal segmental glomerulosclerosis in renal transplantationImmunologic Changes Implicated in the Pathogenesis of Focal Segmental GlomerulosclerosisCrossing the Atlantic: the Euro-Lupus Nephritis regimen in North AmericaPatient-reported outcomes in lupus clinical trials with biologics.Lupus pathobiology based on genomics.Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease.Immunotherapies in Late-Stage Development for Patients With Severe SLE and/or Lupus Nephritis.Recent advances in the understanding of renal inflammation and fibrosis in lupus nephritis.Systemic lupus erythematosus: review of synthetic drugs.Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials.Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicineEfficacy and safety of cyclophosphamide combined with mycophenolate mofetil for induction treatment of class IV lupus nephritis.Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.Drugs in early clinical development for Systemic Lupus Erythematosus.Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.Reviewing the recommendations for lupus in children.Lupus nephritis management guidelines compared.What can we learn from systemic lupus erythematosus pathophysiology to improve current therapy?Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.B cells biology in systemic lupus erythematosus-from bench to bedside.Lupus nephritis and B-cell targeting therapy.Challenges and opportunities in targeting the CD28/CTLA-4 pathway in transplantation and autoimmunity.Towards new avenues in the management of lupus glomerulonephritis.Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art.Hurdles to the introduction of new therapies for immune-mediated kidney diseases.Abatacept for the treatment of systemic lupus erythematosus.Biologics for the treatment of autoimmune renal diseases.Recent advances and current state of immunotherapy in systemic lupus erythematosus.The safety of pharmacological treatment options for lupus nephritis.A critical review of clinical trials in systemic lupus erythematosus.Rethinking biologics in lupus nephritis.Con: Cyclophosphamide for the treatment of lupus nephritis.CD28 Costimulation: From Mechanism to Therapy.Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials.Current and Emerging Therapies for Lupus Nephritis.Update on Biologic Therapies for Systemic Lupus Erythematosus.Overview of pathophysiology and treatment of human lupus nephritis.Insights into the epidemiology and management of lupus nephritis from the US rheumatologist's perspective.Why targeted therapies are necessary for systemic lupus erythematosus.
P2860
Q26740483-96EE23FA-84FC-492A-A550-7A32C0202DE0Q26751470-C8258404-53CF-4334-AD34-45EBD2CE7D6DQ26753833-77DAAA27-39D2-48E6-8065-4216F7BE6251Q28645743-6A7CCE10-21FF-423F-91DB-3E687FB39602Q30391564-48C72EFD-E12C-4935-9EDA-9B5C173AAAEEQ33364409-B1893989-2F49-4F3B-B9B8-D724C7A9315CQ33431030-502065C5-89C0-452A-BA92-CA676BA9E305Q33714219-5D6B3ECF-B077-4C53-B246-2F3D8652DA37Q33806541-9EA34F86-9DDE-4D6B-9E9D-0C1CC3F05F7BQ34498515-5DC6C939-73A5-4631-91F1-7ECAA23F81ACQ35544692-AEB7A93B-3FB0-4038-AD49-56CEE28BF87CQ36088877-7BF0A296-CE20-4841-BB7F-7C44822C20ACQ36493192-F74803E8-598D-4C8A-BC1D-42E7D196E99EQ36919720-B2DEE6BD-63EA-42D2-A920-466C53AF3B78Q37324772-4306755A-7E14-4D73-A22D-43B120E4A793Q37358946-6767487D-0A50-494D-8B0C-575BCD434620Q38374309-B3AB9CEC-AC5E-4BC5-82AE-31A1B3753233Q38446941-3DF4AAC1-CC64-4B73-AF48-419414CD4D57Q38590248-0515300D-BCFB-471C-8FB4-6ECC77F329F9Q38605480-DED861FF-D170-49AB-9EC2-236DC5D742FAQ38631964-7EC1B257-5932-4632-83BB-3C4150CBED36Q38643755-F0CDC571-CCE0-49BC-809B-DB61208880FBQ38681685-479BEE19-1DF6-413E-AFE8-0BCE24EB2E77Q38686467-FB89DDEE-0715-46EC-835D-86F131F4DF36Q38690844-933A3003-5599-45A7-B25F-E827CE6468BDQ38709517-CB50B18B-3133-447F-9255-3AC4216A4FE0Q38734009-ED1A3289-BF60-4FC4-BDEF-35037C933991Q38763327-AEBA2204-1A82-4F5E-8324-CAFBEC99F6B2Q38794663-7AC0340D-CF3D-4E65-8A74-76DEDACD6074Q38829637-2B5FF328-8944-4F7D-B4B4-DF6911253886Q38833868-8C491245-F1A7-44E3-B473-86A35BCB7CCAQ38833873-B3045FFC-5AD9-4754-82DF-18A3F1C5EE86Q38837080-2C66205E-0B9E-49C9-AB88-9187091D9DB2Q38837466-DAC61B1D-6C08-4C96-8823-58D01A9B6CB8Q38840646-6C5C4EA5-E234-4975-9B62-190608A3E2D3Q38855495-6811239C-4FB1-4707-9020-800FC938838CQ38864797-303C8E93-8DF7-4967-9D43-C466B897D21BQ38876110-6ADBD18D-930C-4358-8985-95F3A06962C0Q38877052-CF14EDFA-FD2C-45B5-A095-852C9C52E67AQ38920435-BD0C1C8C-50BD-4567-88C5-541EE5DD7709
P2860
Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Treatment of lupus nephritis w ...... ion Efficacy and Safety Study.
@ast
Treatment of lupus nephritis w ...... ion Efficacy and Safety Study.
@en
type
label
Treatment of lupus nephritis w ...... ion Efficacy and Safety Study.
@ast
Treatment of lupus nephritis w ...... ion Efficacy and Safety Study.
@en
prefLabel
Treatment of lupus nephritis w ...... ion Efficacy and Safety Study.
@ast
Treatment of lupus nephritis w ...... ion Efficacy and Safety Study.
@en
P2860
P356
P1476
Treatment of lupus nephritis w ...... ion Efficacy and Safety Study.
@en
P2093
ACCESS Trial Group
P2860
P304
P356
10.1002/ART.38790
P577
2014-11-01T00:00:00Z